Celgene Corporation (CELG) Stake Raised by Penn Davis Mcfarland Inc.
Penn Davis Mcfarland Inc. increased its stake in Celgene Corporation (NASDAQ:CELG) by 0.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,141 shares of the biopharmaceutical company’s stock after buying an additional 425 shares during the period. Celgene Corporation accounts for approximately 2.7% of Penn Davis Mcfarland Inc.’s investment portfolio, making the stock its 19th largest position. Penn Davis Mcfarland Inc.’s holdings in Celgene Corporation were worth $9,109,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CELG. Motco raised its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the first quarter worth about $118,000. Carroll Financial Associates Inc. increased its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the last quarter. Oakworth Capital Inc. increased its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the last quarter. Finally, Acropolis Investment Management LLC acquired a new position in Celgene Corporation during the second quarter worth about $144,000. 78.34% of the stock is owned by institutional investors.
Celgene Corporation (NASDAQ:CELG) traded down 1.649% during mid-day trading on Thursday, hitting $129.095. 1,907,493 shares of the company traded hands. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The company’s 50-day moving average price is $134.04 and its 200 day moving average price is $124.80. The company has a market capitalization of $101.00 billion, a price-to-earnings ratio of 39.980 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the prior year, the business earned $1.44 EPS. Celgene Corporation’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Stake Raised by Penn Davis Mcfarland Inc.” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/celgene-corporation-celg-stake-raised-by-penn-davis-mcfarland-inc/1500019.html.
A number of research firms have recently issued reports on CELG. Mizuho set a $134.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. Robert W. Baird restated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research report on Friday, July 21st. Jefferies Group LLC restated a “buy” rating and issued a $160.00 price target on shares of Celgene Corporation in a research report on Monday, July 31st. Finally, Cann reiterated a “buy” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $147.00.
In other news, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 253,761 shares of company stock valued at $33,792,445. 0.95% of the stock is owned by company insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.